• In April 2026, Northern Trust reported first-quarter results showing higher net interest income of US$654.0 million and net income of US$525.5 million year over year, alongside continued dividends and completion of a US$863.83 million buyback program.
• At the same time, Northern Trust secured the Sacramento County Employees’ Retirement System mandate, expanded automation for outsourcing clients, and advanced tokenized asset custody via the Canton Network, underscoring how technology and digital assets are reshaping its core servicing model.
• With this backdrop, we’ll examine how winning the SCERS mandate and scaling digital-asset custody influence Northern Trust’s investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 32 companies in the world exploring or producing it. Find the list for free.

Northern Trust Investment Narrative Recap

To own Northern Trust, you need to believe in its ability to compound fee and interest income from complex institutional and wealth clients while keeping costs under control. The latest quarter’s stronger net interest income, higher net income, ongoing dividend, and completed US$863.83 million buyback support that capital strength, but do not materially change the near term catalyst of execution on technology-driven efficiency or the key risk of rising cost and complexity in serving large institutions.

The SCERS win is especially relevant here because it directly reflects confidence in Northern Trust’s technology, outsourcing, and reporting capabilities, which sit at the heart of that efficiency and growth catalyst. Securing a public pension mandate that spans global custody, securities lending, accounting, and integrated reporting illustrates how its investments in automation and middle office infrastructure can translate into deeper, higher value client relationships.

Yet while these wins are encouraging, investors should still focus on the risk that rising client demands and operational complexity could pressure costs and margins over time...

Northern Trust's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2029.

Uncover how Northern Trust's forecasts yield a $153.04 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for Northern Trust span from about US$153 to over US$254,000 per share, underscoring just how far apart individual views can be. Against that backdrop, the recent SCERS mandate and broader outsourcing wins highlight how much the long term outcome may hinge on whether Northern Trust’s technology investments actually translate into sustainable efficiency and profitable growth.

Explore 3 other fair value estimates on Northern Trust - why the stock might be worth 7% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Northern Trust research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Northern Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Northern Trust's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.